GLP-1s in Type 2 Diabetes vs Obesity: Different Goals

The same GLP-1 molecule can be prescribed to two people for very different reasons — one to manage type 2 diabetes, the other to treat obesity — and the goals, the success metrics, and even the dosing can differ between them. This is a common source of confusion, including in news coverage that treats “the weight-loss drug” and “the diabetes drug” as separate things when they are often the same compound aimed at different targets. Semaglutide is the clearest example: it is sold as Ozempic for diabetes and Wegovy for weight management.

Same mechanism, different primary aim

In both settings, the drug works through the incretin system: enhancing glucose-dependent insulin release, suppressing glucagon, slowing gastric emptying, and reducing appetite. What changes is which of those effects is the headline.

The key distinction: in diabetes, glucose control is the primary endpoint and weight loss is a welcome bonus. In obesity, percentage of body weight lost is the primary endpoint and metabolic improvements come along for the ride.

How the endpoints — and doses — differ

The clinical scorecards reflect those different priorities, and the doses often do too. Semaglutide is approved up to 2.0 mg weekly for type 2 diabetes (Ozempic) but up to 2.4 mg weekly for weight management (Wegovy). Liraglutide runs 1.8 mg daily for diabetes (Victoza) versus 3.0 mg daily for obesity (Saxenda) — more appetite suppression is wanted in the weight indication.

	Type 2 diabetes	Obesity
Primary endpoint	Glycemic control (HbA1c)	% body weight lost
Semaglutide dose	up to 2.0 mg/week	up to 2.4 mg/week
Liraglutide dose	up to 1.8 mg/day	up to 3.0 mg/day

Why this matters for expectations

Beetroot, beets, vegetables — illustrating GLP-1s in Type 2 Diabetes vs Obesity: Different Goals

The different framings shape what counts as a good outcome:

Weight expectations differ. People with diabetes on lower doses may see more modest weight loss than those treated specifically for obesity at higher doses. In STEP 1 (semaglutide 2.4 mg, no diabetes) mean weight loss was 14.9%; people on a diabetes dose may lose less. Neither is the drug “not working.”
Cardiovascular evidence is context-specific. Outcome trials tested specific drugs, doses, and populations. LEADER showed liraglutide cut major cardiovascular events 13% in people with diabetes; SELECT showed semaglutide 2.4 mg cut them 20% in people with obesity but without diabetes. A benefit shown in one setting is not a blanket claim for every use.
Coverage and access often hinge on the indication, which is a practical reality rather than a medical one but shapes who gets what.

The takeaway

GLP-1 drugs in diabetes and in obesity share a mechanism but pursue different primary goals, are often dosed differently, and are judged by different endpoints. Recognizing this clears up a lot of apparent contradictions — why two people on “the same drug” report different amounts of weight loss, or why a cardiovascular benefit shown in one trial is not a universal claim. Same tool, different jobs, and the expectations should match the job.